A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine;T-DM1)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Tucatinib (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Cascadian Therapeutics
- 06 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 06 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 24 Jul 2016 Planned End Date changed from 1 May 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History